PRESCRIBING INFORMATION

- **3 BACTROBAN[®] Ointment**
- 4 (mupirocin ointment, 2%)

5 For Dermatologic Use


6 **DESCRIPTION**

- 7 Each gram of BACTROBAN Ointment (mupirocin ointment, 2%) contains 20 mg mupirocin
- 8 in a bland water miscible ointment base (polyethylene glycol ointment, N.F.) consisting of
- 9 polyethylene glycol 400 and polyethylene glycol 3350. Mupirocin is a naturally occurring
- 10 antibiotic. The chemical name is (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-
- 11 methylhexyl]tetrahydro-3,4-dihydroxy- β -methyl-2*H*-pyran-2-crotonic acid, ester with
- 12 9-hydroxynonanoic acid. The molecular formula of mupirocin is $C_{26}H_{44}O_{9}$, and the molecular
- 13 weight is 500.63. The chemical structure is:

14

1

2



15

16 CLINICAL PHARMACOLOGY

17 Application of ¹⁴C-labeled mupirocin ointment to the lower arm of normal male subjects

18 followed by occlusion for 24 hours showed no measurable systemic absorption (<1.1 nanogram

19 mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum

20 corneum of these subjects 72 hours after application.

Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal
 metabolite, monic acid, is eliminated by renal excretion, and demonstrates no antibacterial

23 activity. In a trial conducted in 7 healthy adult male subjects, the elimination half-life after

24 intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to

25 80 minutes for monic acid. The pharmacokinetics of mupirocin has not been studied in

26 individuals with renal insufficiency.

27 **Microbiology:** Mupirocin is an antibacterial agent produced by fermentation using the

- 28 organism Pseudomonas fluorescens. It is active against a wide range of gram-positive bacteria
- 29 including methicillin-resistant *Staphylococcus aureus* (MRSA). It is also active against certain
- 30 gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and
- 31 specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of
- 32 action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial
- 33 agents.

- 34 Resistance occurs rarely. However, when mupirocin resistance does occur, it appears to result
- 35 from the production of a modified isoleucyl-tRNA synthetase. High-level plasmid-mediated
- 36 resistance (MIC >1,024 mcg/mL) has been reported in some strains of S. aureus and
- 37 coagulase-negative staphylococci.
- 38 Mupirocin is bactericidal at concentrations achieved by topical administration. However, the
- 39 minimum bactericidal concentration (MBC) against relevant pathogens is generally 8-fold to
- 40 30-fold higher than the minimum inhibitory concentration (MIC). In addition, mupirocin is
- 41 highly protein-bound (>97%), and the effect of wound secretions on the MICs of mupirocin has
- 42 not been determined.
- 43 Mupirocin has been shown to be active against most strains of *S. aureus* and *Streptococcus*
- 44 pyogenes, both in vitro and in clinical trials (see INDICATIONS AND USAGE). The following
- 45 in vitro data are available, BUT THEIR CLINICAL SIGNIFICANCE IS UNKNOWN.
- 46 Mupirocin is active against most strains of Staphylococcus epidermidis and Staphylococcus
- 47 saprophyticus.

48 INDICATIONS AND USAGE

BACTROBAN Ointment is indicated for the topical treatment of impetigo due to: *S. aureus* and *S. pyogenes*.

51 CONTRAINDICATIONS

52 This drug is contraindicated in patients with known hypersensitivity to any of the constituents 53 of the product.

54 WARNINGS

- 55 Avoid contact with the eyes. In case of accidental contact, rinse well with water.
- 56 In the event of sensitization or severe local irritation from BACTROBAN Ointment, usage 57 should be discontinued.
- 58 *Clostridium difficile-* associated diarrhea (CDAD) has been reported with use of nearly all
- 59 antibacterial agents, including BACTROBAN, and may range in severity from mild diarrhea to
- 60 fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to
- 61 overgrowth of *C. difficile*.
- 62 *C. difficile* produces toxins A and B which contribute to the development of CDAD.
- 63 Hypertoxin producing isolates of *C. difficile* cause increased morbidity and mortality, as these
- 64 infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be
- 65 considered in all patients who present with diarrhea following antibacterial drug use. Careful
- 66 medical history is necessary since CDAD has been reported to occur over two months after the
- 67 administration of antibacterial agents.
- 68 If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against
- 69 C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein
- supplementation, antibacterial treatment of *C. difficile*, and surgical evaluation should be
- 71 instituted as clinically indicated.

72 **PRECAUTIONS**

- As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.
- 75 BACTROBAN Ointment is not formulated for use on mucosal surfaces. Intranasal use has
- been associated with isolated reports of stinging and drying. A paraffin-based formulation —
- 77 BACTROBAN[®] Nasal (mupirocin calcium ointment) is available for intranasal use.
- 78 Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by
- 79 the kidneys. In common with other polyethylene glycol-based ointments, BACTROBAN
- 80 Ointment should not be used in conditions where absorption of large quantities of polyethylene
- 81 glycol is possible, especially if there is evidence of moderate or severe renal impairment.
- 82 BACTROBAN Ointment should not be used with intravenous cannulae or at central 83 intravenous sites because of the potential to promote fungal infections and antimicrobial
- 84 resistance.
- 85 Information for Patients: Use this medication only as directed by the healthcare provider. It is for
- 86 external use only. Avoid contact with the eyes. If BACTROBAN Ointment gets in or near the
- 87 eyes, rinse thoroughly with water. The medication should be stopped and the healthcare provider
- 88 contacted if irritation, severe itching, or rash occurs.
- 89 If impetigo has not improved in 3 to 5 days, contact the healthcare provider.
- 90 **Drug Interactions:** The effect of the concurrent application of BACTROBAN Ointment and
- 91 other drug products has not been studied.

92 **Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to 93 evaluate carcinogenic potential of mupirocin have not been conducted.

- 94 Results of the following studies performed with mupirocin calcium or mupirocin sodium in
- 95 vitro and in vivo did not indicate a potential for genotoxicity: Rat primary hepatocyte
- 96 unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test
- 97 (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse
- 98 lymphoma assay, and bone marrow micronuclei assay in mice.
- 99 Reproduction studies were performed in male and female rats with mupirocin administered
- 100 subcutaneously at doses up to 14 times a human topical dose (approximately 60 mg mupirocin
- 101 per day) on a mg/m² basis and revealed no evidence of impaired fertility and reproductive

102 performance from mupirocin.

- 103 **Pregnancy:** *Teratogenic Effects:* Pregnancy Category B. Reproduction studies have been
- 104 performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 22 and
- 105 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) on a
- 106 mg/m^2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however,
- 107 no adequate and well-controlled studies in pregnant women. Because animal studies are not
- 108 always predictive of human response, this drug should be used during pregnancy only if clearly
- 109 needed.

- 110 **Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many
- 111 drugs are excreted in human milk, caution should be exercised when BACTROBAN Ointment is
- administered to a nursing woman.
- 113 **Pediatric Use:** The safety and effectiveness of BACTROBAN Ointment have been established
- in the age range of 2 months to 16 years. Use of BACTROBAN Ointment in these age groups is
- supported by evidence from adequate and well-controlled trials of BACTROBAN Ointment in
- 116 impetigo in pediatric subjects studied as a part of the pivotal clinical trials (see CLINICAL
- 117 STUDIES).

118 **ADVERSE REACTIONS**

- 119 The following local adverse reactions have been reported in connection with the use of
- 120 BACTROBAN Ointment: burning, stinging, or pain in 1.5% of subjects; itching in 1% of
- subjects; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increasedexudate in less than 1% of subjects.
- 123 Systemic allergic reactions, including anaphylaxis, urticaria, angioedema and generalized rash
- 124 have been reported in patients treated with BACTROBAN formulations

125 **DOSAGE AND ADMINISTRATION**

- 126 A small amount of BACTROBAN Ointment should be applied to the affected area 3 times
- 127 daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a
- 128 clinical response within 3 to 5 days should be re-evaluated.

129 CLINICAL STUDIES

- The efficacy of topical BACTROBAN Ointment in impetigo was tested in 2 trials. In the first,
 subjects with impetigo were randomized to receive either BACTROBAN O or vehicle placebo 3
- times daily for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations
- 133 (adults and pediatric subjects included) were 71% for BACTROBAN Ointment (n = 49) and 134 35% for vehicle placebo (n = 51). Pathogen eradication rates in the evaluable populations were
- 94% for BACTROBAN Ointment and 62% for vehicle placebo. There were no side effects
- 136 reported in the group receiving BACTROBAN Ointment.
- 137 In the second trial, subjects with impetigo were randomized to receive either BACTROBAN
- 138 Ointment 3 times daily or 30 to 40 mg/kg oral erythromycin ethylsuccinate per day (this was an
- 139 unblinded trial) for 8 days. There was a follow-up visit 1 week after treatment ended. Clinical
- 140 efficacy rates at the follow-up visit in the evaluable populations (adults and pediatric subjects
- included) were 93% for BACTROBAN Ointment (n = 29) and 78.5% for erythromycin (n = 28).
- 142 Pathogen eradication rates in the evaluable populations were 100% for both test groups. There
- 143 were no side effects reported in the group receiving BACTROBAN Ointment.
- 144 **Pediatrics:** There were 91 pediatric subjects aged 2 months to 15 years in the first trial
- described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78%
- 146 for BACTROBAN Ointment (n = 42) and 36% for vehicle placebo (n = 49). In the second trial
- 147 described above, all subjects were pediatric except 2 adults in the group receiving

- 148 BACTROBAN Ointment. The age range of the pediatric subjects was 7 months to 13 years. The
- 149 clinical efficacy rate for BACTROBAN Ointment (n = 27) was 96%, and for erythromycin it was
- 150 unchanged (78.5%).

151 HOW SUPPLIED

- 152 BACTROBAN Ointment is supplied in 22-gram tubes.
- 153 NDC 0029-1525-44 (22-gram tube)
- 154 Store at controlled room temperature 20° to 25° C (68° to 77° F).
- 155

gsk GlaxoSmithKline

- 156
- 157 GlaxoSmithKline
- 158 Research Triangle Park, NC 27709
- 159
- 160 BACTROBAN, BACTROBAN Ointment, and BACTROBAN Nasal are registered trademarks
- 161 of the GlaxoSmithKline group of companies.
- 162
- 163 ©2014, GlaxoSmithKline group of companies. All rights reserved.
- 164
- 165 May/2014
- 166 BBM: xxPI
- 167

PRESCRIBING INFORMATION


2 BACTROBAN[®] Nasal

3 (mupirocin calcium ointment, 2%)

4 for intranasal use only

5 **DESCRIPTION**

- 6 BACTROBAN Nasal (mupirocin calcium ointment, 2%) contains the dihydrate crystalline
- 7 calcium hemi-salt of the antibiotic mupirocin. Chemically, it is $(\alpha E, 2S, 3R, 4R, 5S)$ -5-
- 8 [(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy- β -methyl-2*H*-
- 9 pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.
- 10 The molecular formula of mupirocin calcium is $(C_{26}H_{43}O_9)_2Ca\bullet 2H_2O$, and the molecular
- 11 weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula
- 12 of mupirocin calcium is:



13

1

14 BACTROBAN Nasal is a white to off-white ointment that contains 2.15% w/w mupirocin

15 calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive

16 ingredients are paraffin and a mixture of glycerin esters (SOFTISAN[®] 649).

17 CLINICAL PHARMACOLOGY

18 **Pharmacokinetics:** Following single or repeated intranasal applications of 0.2 gram of

19 BACTROBAN Nasal 3 times daily for 3 days to 5 healthy adult male subjects, no evidence of

20 systemic absorption of mupirocin was demonstrated. The dosage regimen used in this trial was

21 for pharmacokinetic characterization only (see DOSAGE AND ADMINISTRATION for proper

22 clinical dosing information).

In this trial, the concentrations of mupirocin in urine and of monic acid in urine and serum were below the limit of determination of the assay for up to 72 hours after the applications. The lowest levels of determination of the assay used were 50 ng/mL of mupirocin in urine, 75 ng/mL of monic acid in urine, and 10 ng/mL of monic acid in serum. Based on the detectable limit of the urine assay for monic acid, one can extrapolate that a mean of 3.3% (range: 1.2 to 5.1%) of the applied dose could be systemically absorbed from the nasal mucosa of **adults**.

- 29 Data from a report of a pharmacokinetic trial in neonates and premature infants indicate that,
- 30 unlike in adults, significant systemic absorption occurred following intranasal administration of
- 31 BACTROBAN Nasal in this population. At this time, the pharmacokinetic properties of
- 32 mupirocin following intranasal application of BACTROBAN Nasal have not been

- 33 adequately characterized in neonates or other children younger than 12 years, and in
- 34 addition, the safety of the product in children younger than 12 years has not been
- 35 established.
- The effect of the concurrent application of intranasal mupirocin calcium ointment, 2% with other intranasal products has not been studied (see PRECAUTIONS, Drug Interactions).
- 38 Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal
- 39 metabolite, monic acid, demonstrates no antibacterial activity. In a trial conducted in 7 healthy
- 40 adult male subjects, the elimination half-life after intravenous administration of mupirocin was
- 41 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. Monic acid is
- 42 predominantly eliminated by renal excretion. The pharmacokinetics of mupirocin has not been43 studied in individuals with renal insufficiency.
- 44 **Microbiology**: Mupirocin is an antibacterial agent produced by fermentation using the
- 45 organism *Pseudomonas fluorescens*.
- 46 **Mechanism of Action:** Mupirocin inhibits bacterial protein synthesis by reversibly and
- 47 specifically binding to bacterial isoleucyl transfer-RNA synthetase.
- 48 Mupirocin is bactericidal at concentrations achieved by topical intranasal administration.
- 49 Mupirocin is highly protein bound (>97%), and the effect of nasal secretions on the MICs of
- 50 intranasally applied mupirocin has not been determined.
- 51 **Mechanism of Resistance:** When mupirocin resistance occurs, it results from the
- 52 production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a
- 53 plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance
- 54 (MIC >512 mcg/mL) has been reported in increasing numbers of isolates of *Staphylococcus*
- 55 *aureus* and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance
- 56 occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci.
- 57 **Cross Resistance**: Due to its mode of action, mupirocin does not demonstrate cross-
- 58 resistance with other classes of antimicrobial agents.
- 59 **Susceptibility Testing**: While it is suggested that isolates of *S. aureus* with a minimal
- 60 inhibitory concentration (MIC) of <256 mcg/mL (absence of high level resistance to mupirocin)
- 61 may be successfully eliminated from the nares, this criteria should be evaluated at each medical
- 62 facility in conjunction with laboratory, medical and infection control staff.¹
- 63
- 64 Correlation of Bactroban Nasal in vitro activity and MRSA nasal decolonization has been
- 65 demonstrated in clinical trials (see CLINICAL STUDIES).

66 INDICATIONS AND USAGE

- 67 BACTROBAN Nasal is indicated for the eradication of nasal colonization with
- 68 methicillin-resistant S. aureus in adult patients and health care workers as part of a
- 69 comprehensive infection control program to reduce the risk of infection among patients at high
- 70 risk of methicillin-resistant S. aureus infection during institutional outbreaks of infections with
- 71 this pathogen.

72 **NOTE:**

- 1. There are insufficient data at this time to establish that this product is safe and effective as
- 74 part of an intervention program to prevent autoinfection of high-risk patients from their own
- 75 nasal colonization with *S. aureus*.
- There are insufficient data at this time to recommend use of BACTROBAN Nasal for general
 prophylaxis of any infection in any patient population.
- 78 3. Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2
- to 4 days after therapy was completed. Approximately 30% recolonization was reported in 1
- 80 domestic trial within 4 weeks after completion of therapy. These eradication rates were
- 81 clinically and statistically superior to those reported in subjects in the vehicle-treated arms of
- the adequate and well-controlled trials. Those treated with vehicle had eradication rates of
 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.
- All adequate and well-controlled trials of this product were vehicle-controlled; therefore, no
- 85 data from direct, head-to-head comparisons with other products are available at this time.

86 CONTRAINDICATIONS

87 BACTROBAN Nasal is contraindicated in patients with known hypersensitivity to any of the 88 constituents of the product.

89 WARNINGS

- 90 AVOID CONTACT WITH THE EYES. In case of accidental contact, rinse well with
- 91 water. Application of BACTROBAN Nasal to the eye under testing conditions has caused severe
- 92 symptoms such as burning and tearing. These symptoms resolved within days to weeks after
- 93 discontinuation of the ointment. In the event of a sensitization or severe local irritation from
- 94 BACTROBAN Nasal, usage should be discontinued.
- 95 *Clostridium difficile-* associated diarrhea (CDAD) has been reported with use of nearly all
- antibacterial agents, including BACTROBAN, and may range in severity from mild diarrhea to
 fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to
 overgrowth of *C. difficile*.
- 99 *C. difficile* produces toxins A and B which contribute to the development of CDAD.
- 100 Hypertoxin producing isolates of *C. difficile* cause increased morbidity and mortality, as these
- 101 infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be
- 102 considered in all patients who present with diarrhea following antibacterial drug use. Careful
- 103 medical history is necessary since CDAD has been reported to occur over two months after the
- 104 administration of antibacterial agents.
- 105 If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against *C*.
- 106 *difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein
- 107 supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be
- 108 instituted as clinically indicated.

109 **PRECAUTIONS**

- 110 **General:** As with other antibacterial products, prolonged use may result in overgrowth of
- 111 nonsusceptible microorganisms, including fungi (see DOSAGE AND ADMINISTRATION).

112 **Information for Patients:** Patients should be given the following instructions:

- Apply approximately one-half of the ointment from the single-use tube directly into 1 nostril
 and the other half into the other nostril;
- Avoid contact of the medication with the eyes; if BACTROBAN Nasal gets in or near the eyes,
 rinse thoroughly with water.
- 117 Discard the tube after using, do not re-use;
- Press the sides of the nose together and gently massage after application to spread the
 ointment throughout the inside of the nostrils; and
- Discontinue usage of the medication and call the healthcare practitioner if sensitization or
 severe local irritation occurs.

122 **Drug Interactions:** The effect of the concurrent application of intranasal mupirocin calcium

and other intranasal products has not been studied. Until further information is known, mupirocincalcium ointment, 2% should not be applied concurrently with any other intranasal products.

125 **Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to 126 evaluate carcinogenic potential of mupirocin calcium have not been conducted.

- 127 Results of the following studies performed with mupirocin calcium or mupirocin sodium in
- 128 vitro and in vivo did not indicate a potential for mutagenicity: Rat primary hepatocyte
- 129 unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test
- 130 (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse

131 lymphoma assay, and bone marrow micronuclei assay in mice.

- 132 Reproduction studies were performed in rats with mupirocin administered subcutaneously at
- 133 doses up to **40** times the human intranasal dose (approximately 20 mg mupirocin per day) on a
- 134 mg/m^2 basis and revealed no evidence of impaired fertility from mupirocin sodium.
- 135 Pregnancy: *Teratogenic Effects:* Pregnancy Category B. Reproduction studies have been 136 performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and
- 137 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on
- 138 a mg/m^2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are,
- 139 however, no adequate and well-controlled studies in pregnant women. Because animal
- 140 reproduction studies are not always predictive of human response, this drug should be used
- 141 during pregnancy only if clearly needed.

142 **Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many

drugs are excreted in human milk, caution should be exercised when BACTROBAN Nasal isadministered to a nursing woman.

- 145 **Pediatric Use:** Safety in children younger than 12 years has not been established (See
- 146 CLINICAL PHARMACOLOGY).

147 **ADVERSE REACTIONS**

- 148 **Clinical Trials:** In clinical trials, 210 domestic and 2,130 foreign adult subjects received
- 149 BACTROBAN Nasal ointment. Less than 1% of domestic or foreign subjects in clinical trials
- 150 were withdrawn due to adverse events.
- 151 The most frequently reported adverse events in foreign clinical trials were as follows: rhinitis
- 152 (1.0%), taste perversion (0.8%), pharyngitis (0.5%).
- 153 In domestic clinical trials, 17% (36/210) of adults treated with BACTROBAN Nasal ointment
- reported adverse events thought to be at least possibly drug-related. The incidence of adverse
- events that were reported in at least 1% of adults enrolled in domestic clinical trials were as
- 156 follows:
- 157

Adverse Events	% of Subjects Experiencing Event BACTROBAN Nasal (n = 210)
Headache	9%
Rhinitis	6%
Respiratory disorder, including upper respiratory tract congestion	5%
Pharyngitis	4%
Taste perversion	3%
Burning/stinging	2%
Cough	2%
Pruritus	1%

158 Table 1. Adverse Events (≥1% Incidence) – Adults in US Trials

159

160 The following events thought possibly drug-related were reported in less than 1% of adults

161 enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea,162 and rash.

163 All adequate and well-controlled clinical trials have been performed using BACTROBAN

- 164 Nasal ointment, 2% in 1 arm and the vehicle ointment in the other arm of the trial. No adequate
- and well-controlled safety data are available from direct, head-to-head comparative studies of
- 166 this product and other products for this indication.

167 Systemic allergic reactions, including anaphylaxis, urticaria, angioedema and

168 generalized rash have been reported in patients treated with BACTROBAN formulations.

169 **OVERDOSAGE**

- 170 Following single or repeated intranasal applications of BACTROBAN Nasal to adults, no
- 171 evidence for systemic absorption of mupirocin was obtained. Intravenous infusions of 252 mg, as
- 172 well as single oral doses of 500 mg of mupirocin, have been well tolerated in healthy adult

- 173 subjects. There is no information regarding local overdose of BACTROBAN Nasal or regarding
- 174 oral ingestion of the nasal ointment formulation.

175 DOSAGE AND ADMINISTRATION

- 176 (See INDICATIONS AND USAGE.)
- Adults (aged 12 years and older): Approximately one-half of the ointment from the single-use
 tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning
 and evening) for 5 days.
- After application, the nostrils should be closed by pressing together and releasing the sides ofthe nose repetitively for approximately 1 minute. This will spread the ointment throughout the
- 182 nares.
- 183 The single-use 1.0-gram tube will deliver a total of approximately 0.5 grams of the ointment
- 184 (approximately 0.25 grams/nostril).

185 The tube should be discarded after usage; it should not be re-used.

186 The safety and effectiveness of applications of this medication for greater than 5 days have

187 not been established. There are no human clinical or pre-clinical animal data to support the use

of this product in a chronic manner or in manners other than those described in this packageinsert.

- 190 Until further information is known, BACTROBAN Nasal should not be applied concurrently
- 191 with any other intranasal products.

192 HOW SUPPLIED

- 193 BACTROBAN Nasal is supplied in 1.0-gram tubes.
- 194 NDC 0029-1526-11 (package of 10 single-tube cartons).
- 195 Store between 20° and $25^{\circ}C$ (68° and 77°F); excursions permitted to $15^{\circ}-30^{\circ}C$ (59°-86°F).
- 196 Do not refrigerate.

197 **REFERENCE**

- 198 1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial
- 199 Susceptibility Testing; 22nd Informational Supplement. CLSI document M100-S22. CLSI, 950
- 200 West Valley Rd., Suite 2500, Wayne, PA, 19087, 2012.
- 201
- 202 BACTROBAN and BACTROBAN Nasal are registered trademarks of the GlaxoSmithKline
- 203 group of companies.
- 204 SOFTISAN is a registered trademark of Sasol Olefins & Surfactants GmbH.
- 205

gSk GlaxoSmithKline

206

- 207 GlaxoSmithKline
- 208 Research Triangle Park, NC 27709

209

210 ©2014, GlaxoSmithKline group of companies. All rights reserved.

211


- 212 May/2014
- 213 BBN:xxPI

PRESCRIBING INFORMATION

- 2 **BACTROBAN[®] Cream**
- 3 (mupirocin calcium cream, 2%)
- 4 For Dermatologic Use

5 **DESCRIPTION**

- 6 BACTROBAN Cream (mupirocin calcium cream, 2%) contains the dihydrate crystalline
- 7 calcium hemi-salt of the antibiotic mupirocin. Chemically, it is $(\alpha E, 2S, 3R, 4R, 5S)$ -5-
- 8 $[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-\beta-methyl-2H-$
- 9 pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.
- 10 The molecular formula of mupirocin calcium is $(C_{26}H_{43}O_9)_2Ca\bullet 2H_2O$, and the molecular
- 11 weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula
- 12 of mupirocin calcium is:



13

1

14 BACTROBAN Cream is a white cream that contains 2.15% w/w mupirocin calcium

15 (equivalent to 2.0% mupirocin free acid) in an oil and water-based emulsion. The inactive

- 16 ingredients are benzyl alcohol, cetomacrogol 1000, cetyl alcohol, mineral oil, phenoxyethanol,
- 17 purified water, stearyl alcohol, and xanthan gum.

18 CLINICAL PHARMACOLOGY

Pharmacokinetics: Systemic absorption of mupirocin through intact human skin is minimal.
 The systemic absorption of mupirocin was studied following application of BACTROBAN
 Cream 3 times daily for 5 days to various skin lesions (>10 cm in length or 100 cm² in area) in
 16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption

- was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from
- this trial indicated more frequent occurrence of percutaneous absorption in children (90% of
- 25 subjects) compared with adults (44% of subjects); however, the observed urinary concentrations

26 in children (0.07 to 1.3 mcg/mL [1 pediatric subjects), no wever, the observed annually concentrations

- 27 observed range (0.08 to 10.03 mcg/mL [9 adults had no detectable level]) in the adult population.
- 28 In general, the degree of percutaneous absorption following multiple dosing appears to be
- 29 minimal in adults and children. Any mupirocin reaching the systemic circulation is rapidly
- 30 metabolized, predominantly to inactive monic acid, which is eliminated by renal excretion.
- 31 **Microbiology:** Mupirocin is an antibacterial agent produced by fermentation using the
- 32 organism *Pseudomonas fluorescens*. It is active against a wide range of gram-positive bacteria
- 33 including methicillin-resistant *Staphylococcus aureus* (MRSA). It is also active against certain
- 34 gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and

- 35 specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of
- 36 action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial
- 37 agents.
- 38 Resistance occurs rarely; however, when mupirocin resistance does occur, it appears to result
- 39 from the production of a modified isoleucyl-tRNA synthetase. High-level plasmid-mediated
- 40 resistance (MIC >1,024 mcg/mL) has been reported in some strains of *Staphylococcus aureus*
- 41 and coagulase-negative staphylococci.
- 42 Mupirocin is bactericidal at concentrations achieved by topical application. The minimum
- 43 bactericidal concentration (MBC) against relevant pathogens is generally 8-fold to 30-fold higher
- than the minimum inhibitory concentration (MIC). In addition, mupirocin is highly protein
- bound (>97%), and the effect of wound secretions on the MICs of mupirocin has not beendetermined.
- 47 Mupirocin has been shown to be active against most strains of *S. aureus* and *Streptococcus*
- 48 *pyogenes*, both in vitro and in clinical trials (see INDICATIONS AND USAGE). The following
- 49 in vitro data are available, BUT THEIR CLINICAL SIGNIFICANCE IS UNKNOWN.
- 50 Mupirocin is active against most strains of *Staphylococcus epidermidis* and *Staphylococcus*
- 51 saprophyticus.

52 INDICATIONS AND USAGE

53 BACTROBAN Cream is indicated for the treatment of secondarily infected traumatic skin 54 lesions (up to 10 cm in length or 100 cm² in area) due to susceptible strains of *S. aureus* and *S.* 55 *pyogenes*.

56 **CONTRAINDICATIONS**

57 BACTROBAN Cream is contraindicated in patients with known hypersensitivity to any of the 58 constituents of the product.

59 WARNINGS

- 60 Avoid contact with the eyes. In case of accidental contact, rinse well with water.
- 61 In the event of a sensitization or severe local irritation from BACTROBAN Cream, usage
- 62 should be discontinued, and appropriate alternative therapy for the infection instituted.

63 *Clostridium difficile-* associated diarrhea (CDAD) has been reported with use of nearly all

64 antibacterial agents, including BACTROBAN, and may range in severity from mild diarrhea to

65 fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to

- 66 overgrowth of *C. difficile*.
- 67 *C. difficile* produces toxins A and B which contribute to the development of CDAD.
- 68 Hypertoxin producing isolates of *C. difficile* cause increased morbidity and mortality, as these
- 69 infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be
- 70 considered in all patients who present with diarrhea following antibacterial drug use. Careful
- 71 medical history is necessary since CDAD has been reported to occur over two months after the
- 72 administration of antibacterial agents.

- 73 If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against *C*.
- 74 *difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein
- supplementation, antibacterial treatment of *C. difficile*, and surgical evaluation should be
- 76 instituted as clinically indicated.

77 **PRECAUTIONS**

- 78 **General:** As with other antibacterial products, prolonged use may result in overgrowth of
- 79 nonsusceptible microorganisms, including fungi (see DOSAGE AND ADMINISTRATION).
- 80 BACTROBAN Cream is not formulated for use on mucosal surfaces.

81 Information for Patients:

- Use this medication only as directed by the healthcare provider. It is for external use only.
 Avoid contact with the eyes. If BACTROBAN Cream gets in or near the eyes, rinse thoroughly
 with water.
- The treated area may be covered by gauze dressing if desired.
- Report to the healthcare provider any signs of local adverse reactions. The medication should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs.
- If no improvement is seen in 3 to 5 days, contact the healthcare provider.
- 89 **Drug Interactions:** The effect of the concurrent application of topical mupirocin calcium
- 90 cream and other topical products has not been studied.
- 91 **Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to 92 evaluate carcinogenic potential of mupirocin calcium have not been conducted.
- 93 Results of the following studies performed with mupirocin calcium or mupirocin sodium in
- 94 vitro and in vivo did not indicate a potential for mutagenicity: Rat primary hepatocyte
- 95 unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test
- 96 (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse
- 97 lymphoma assay, and bone marrow micronuclei assay in mice.
- Fertility studies were performed in rats with mupirocin administered subcutaneously at doses
 up to 49 times a human topical dose of 1 gram/day (approximately 20 mg mupirocin per day) on
- 100 a mg/m^2 basis and revealed no evidence of impaired fertility from mupirocin sodium.
- 101 Pregnancy: Teratogenic Effects: Pregnancy Category B. Teratology studies have been
- 102 performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 78 and
- 103 154 times, respectively, a human topical dose of 1 gram/day (approximately 20 mg mupirocin
- 104 per day) on a mg/m^2 basis and revealed no evidence of harm to the fetus due to mupirocin. There
- are, however, no adequate and well-controlled studies in pregnant women. Because animal
- 106 reproduction studies are not always predictive of human response, this drug should be used 107 during pregnancy only if clearly needed.
- 108 **Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many
- 109 drugs are excreted in human milk, caution should be exercised when BACTROBAN Cream is
- administered to a nursing woman.

- 111 **Pediatric Use:** The safety and effectiveness of BACTROBAN Cream have been established in
- the age groups 3 months to 16 years. Use of BACTROBAN Cream in these age groups is
- supported by evidence from adequate and well-controlled trials of BACTROBAN CREAM in
- adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults
- 115 (see CLINICAL STUDIES).
- 116 **Geriatric Use:** In 2 well-controlled trials, 30 subjects older than 65 years were treated with
- 117 BACTROBAN Cream. No overall difference in the efficacy or safety of BACTROBAN Cream
- 118 was observed in this patient population when compared with that observed in younger patients.

119 **ADVERSE REACTIONS**

- 120 In 2 randomized, double-blind, double-dummy trials, 339 subjects were treated with topical
- 121 BACTROBAN Cream plus oral placebo. Adverse events thought to be possibly or probably
- 122 drug-related occurred in 28 (8.3%) subjects. The incidence of those events that were reported in
- 123 at least 1% of subjects enrolled in these trials were: headache (1.7%), rash, and nausea (1.1%
- 124 each).
- 125 Other adverse events thought to be possibly or probably drug-related which occurred in less
- 126 than 1% of subjects were: abdominal pain, burning at application site, cellulitis, dermatitis,
- 127 dizziness, pruritus, secondary wound infection, and ulcerative stomatitis.
- 128 In a supportive trial in the treatment of secondarily infected eczema, 82 subjects were treated
- 129 with BACTROBAN Cream. The incidence of adverse events thought to be possibly or probably
- 130 drug-related was as follows: nausea (4.9%), headache, and burning at application site (3.6%
- each), pruritus (2.4%) and 1 report each of abdominal pain, bleeding secondary to eczema, pain
- 132 secondary to eczema, hives, dry skin, and rash.
- Systemic allergic reactions, including anaphylaxis, urticaria, angioedema and generalized rash
 have been reported in patients treated with BACTROBAN formulations.

135 **OVERDOSAGE**

- 136 Intravenous infusions of 252 mg, as well as single oral doses of 500 mg of mupirocin, have
- been well tolerated in healthy adult subjects. There is no information regarding overdose of
- 138 BACTROBAN Cream.

139 DOSAGE AND ADMINISTRATION

- 140 A small amount of BACTROBAN Cream should be applied to the affected area 3 times daily
- 141 for 10 days. The area treated may be covered with gauze dressing if desired. Patients not
- showing a clinical response within 3 to 5 days should be re-evaluated.

143 CLINICAL STUDIES

- 144 The efficacy of topical BACTROBAN Cream for the treatment of secondarily infected
- traumatic skin lesions (e.g., lacerations, sutured wounds, and abrasions not more than 10 cm in
- length or 100 cm^2 in total area) was compared with that of oral cephalexin in 2 randomized,
- 147 double-blind, double-dummy clinical trials. Clinical efficacy rates at follow-up in the per-

- 148 protocol populations (adults and pediatric subjects included) were 96.1% for BACTROBAN
- 149 Cream (n = 231) and 93.1% for oral cephalexin (n = 219). Pathogen eradication rates at
- 150 follow-up in the per-protocol populations were 100% for both BACTROBAN Cream and oral
- 151 cephalexin.
- 152 **Pediatrics:** There were 93 pediatric subjects aged 2 weeks to 16 years enrolled per protocol in
- 153 the secondarily infected skin lesion trials, although only 3 were less than 2 years of age in the
- 154 population treated with BACTROBAN Cream. Subjects were randomized to either 10 days of
- topical BACTROBAN Cream 3 times daily or 10 days of oral cephalexin (250 mg 4 times daily
- 156 for subjects >40 kg or 25 mg/kg/day oral suspension in 4 divided doses for subjects \leq 40 kg).
- 157 Clinical efficacy at follow-up (7 to 12 days post-therapy) in the per-protocol populations was
- 158 97.7% (43/44) for BACTROBAN Cream and 93.9% (46/49) for cephalexin. Only 1 adverse
- 159 event (headache) was thought to be possibly or probably related to drug therapy with
- 160 BACTROBAN Cream in the intent-to-treat pediatric population of 70 children (1.4%).

161 HOW SUPPLIED

- 162 BACTROBAN Cream is supplied in 15-gram and 30-gram tubes.
- 163 NDC 0029-1527-22 (15-gram tube)
- 164 NDC 0029-1527-25 (30-gram tube)
- 165 Store at or below 25°C (77°F). Do not freeze.
- 166

SSK GlaxoSmithKline

- 167 168 GlaxoSmithKline
- 169 Research Triangle Park, NC 27709
- 170
- 171 BACTROBAN and BACTROBAN Cream are registered trademarks of the GlaxoSmithKline
- 172 group of companies.
- 173
- 174 ©2014, GlaxoSmithKline group of companies. All rights reserved.
- 175
- 176 May/2014
- 177 BBC:xxPI